The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 31, 2023

Filed:

Jul. 23, 2021
Applicants:

Massachusetts Institute of Technology, Cambridge, MA (US);

Orna Therapeutics, Inc., Cambridge, MA (US);

Inventors:

Robert Alexander Wesselhoeft, Cambridge, MA (US);

Daniel G. Anderson, Cambridge, MA (US);

Shinichiro Fuse, Cambridge, MA (US);

Brian Goodman, Cambridge, MA (US);

Allen T. Horhota, Cambridge, MA (US);

Raffaella Squilloni, Cambridge, MA (US);

Assignee:

Orna Therapeutics, Inc., Cambridge, MA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 48/00 (2006.01); C07K 14/725 (2006.01); A61K 9/51 (2006.01); A61K 35/17 (2015.01); C07K 16/28 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/7051 (2013.01); A61K 9/51 (2013.01); A61K 35/17 (2013.01); C07K 16/28 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); C07K 2319/30 (2013.01); C12N 2310/532 (2013.01); C12N 2840/203 (2013.01); C12N 2840/60 (2013.01);
Abstract

Circular RNA and transfer vehicles, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes a chimeric antigen receptor (CAR). In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.


Find Patent Forward Citations

Loading…